PTPaula Tormos-Pons

Paula Tormos-Pons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Paula Tormos-Pons has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Cognitive reserve and memory in temporal lobe epilepsy and caregivers: a comparative pilot study

    by Raquel Ferrer-Ricart, Irene Cano-López, Judit Catalán-Aguilar, Kevin G. Hampel, Paula Tormos-Pons, Teresa Vicente-Hernández, Vicente Villanueva, Esperanza González-Bono

    Drug-resistant epilepsy is characterized by chronic exposure to uncontrollable and unpredictable seizures, resulting in sustained physiological and emotional overload, which supports its conceptual...

  • Open Access

    Affective and Cognitive Vulnerability Under Chronic Stress: Insights From Patients With Left Temporal Lobe Epilepsy and Caregivers

    by Teresa Vicente-Hernández, Irene Cano-López, Judit Catalán-Aguilar, Paula Tormos-Pons, Kevin G. Hampel, Raquel Ferrer-Ricart, Esperanza González-Bono, Vicente Villanueva

    Background: Temporal lobe epilepsy (TLE) is a chronic stress condition characterized by affective and cognitive deficits. This study analyzed differences in affective and cognitive functioning between patients with TLE and another chronically stressed population — caregivers of patients with epilepsy — as well as the relationships between affective and cognitive outcomes. Methods: In this cross-sectional study, 40 adults (20 with left TLE and 20 caregivers; mean age 48.43 ± 8.86 years) underwent a neuropsychological assessment evaluating affectivity, attention, executive function, language, and memory. Results: Patients with TLE and caregivers did not differ in anxiety, depression, attention, executive functions, or visual memory. However, patients with TLE had poorer semantic verbal fluency (p = 0.02), naming (p < 0.0001), short-term verbal recall (p = 0.027), long-term verbal recall with semantic cues (p = 0.005), long-term verbal recognition (p = 0.017), and verbal discriminability (p = 0.001). The group (epilepsy vs. caregiver) significantly moderated the association between depression and long-term verbal recognition (B = –0.12, standard error (SE) = 0.05, p = 0.03, 95% confidence interval (CI) [–0.23, –0.01]), with higher depression scores being associated with poorer verbal recognition in patients with epilepsy (p = 0.001) but not in caregivers (p = 0.74). Conclusions: These findings suggest a specific pattern of verbal dysfunction and increased cognitive vulnerability to depression in patients with TLE, compared to another chronically stressed group. Although the present study cannot determine the mechanisms underlying these associations, the results underscore the clinical relevance of assessing these variables together and may inform the development of tailored interventions.


  • Open Access

    Sex and gender differences in memory in epilepsy: a systematic review and meta-analysis

    by Paula Tormos-Pons, Esperanza González-Bono, Irene Cano-López

    Background: Memory impairments are highly prevalent in patients with epilepsy, yet important gaps remain in the understanding of potential sex and gender differences. This systematic review and meta-analysis aim to synthesize the available evidence on sex and gender differences in memory functioning in adults and children with epilepsy, and to explore the relevance of the epilepsy type, the side of seizure focus, the hemispheric dominance for language, the educational level and the age group in these differences. Methods: The study followed PRISMA guidelines and was registered in PROSPERO (CRD420251006928). Studies were retrieved from Web of Science, PubMed/MEDLINE, Embase, and Scopus. Results: The systematic search yielded 1,261 records, from which 32 studies were selected. Women scored higher than men in immediate verbal memory, both at baseline ( g = 0.34; 95% CI = 0.23, 0.44; p < 0.0001) and after epilepsy surgery ( g = 0.30; 95% CI = 0.15, 0.44; p < 0.0001). This advantage was also observed in delayed verbal memory, at baseline ( g = 0.30; 95% CI = 0.19, 0.41; p < 0.0001) and after surgery ( g = 0.25; 95% CI = 0.09, 0.41; p = 0.0018). In contrast, men outperformed women in immediate visual memory, both before ( g = -0.13; 95% CI = -0.22, -0.03; p = 0.01) and after surgery ( g = -0.17; 95% CI = -0.33, -0.01; p = 0.04). No significant differences were observed in working memory or delayed visual memory. Effect sizes favoring women in verbal memory were significantly smaller in studies including only patients with temporal lobe epilepsy compared to mixed epilepsy types. The effect size for postsurgical delayed verbal memory was moderated by the side of seizure focus: studies including a greater proportion of patients with left-hemisphere epilepsy showed poorer postsurgical delayed verbal memory. Hemispheric dominance for language, age, and educational level did not moderate sex-gender differences in memory. Conclusions: These findings underscore the importance of incorporating sex and gender variables in neuropsychological assessment and intervention planning, offering evidence-based recommendations.


  • Open Access

    Prospective study of cenobamate on cognition, affectivity, and quality of life in focal epilepsy

    by Judit Catalán‐Aguilar, Kevin G. Hampel, Irene Cano‐López, Mercedes Garcés, Alejandro Lozano‐García, Paula Tormos‐Pons, Esperanza González‐Bono, Vicente Villanueva

    Objective: Cenobamate is a recently approved antiseizure medication that proved to be safe and effective in randomized controlled trials. However, little is known about its impact on some areas frequently affected by epilepsy. For this reason, we explored the effects of cenobamate on cognitive performance, as well as on negative affectivity and quality of life in a sample of patients with drug‐resistant epilepsy.Methods: Two prospective cohort studies were carried out. In Study 1, 32 patients (22 men and 10 women) underwent a baseline (T0) and a short‐term (T1) neuropsychological assessment after 3 months of cenobamate administration. In Study 2, 22 patients (16 men and 6 women) from the T1 sample also underwent a baseline and a follow‐up evaluation (T2) 6 months after T0.Results: No significant differences were found in cognitive variables, negative affectivity, and quality of life either in Study 1 or Study 2. Similarly, based on the reliable change index, it was found that most patients showed no changes in these variables.Significance: These results suggest that cenobamate is a safe antiseizure medication in terms of cognition, negative affectivity, or quality of life since no adverse events have been found after 3 and 6 months of treatment.Plain Language Summary: Cenobamate is a new antiseizure medication. In patients with epilepsy, cenobamate seems to not affect cognition, anxiety, depression, or quality of life.